TX-MARY-KAY
Mary Kay Inc. , a decades-long pioneer and innovator in skincare research, recently provided an educational grant to the International Master Course on Aging Science (IMCAS ) Academy to fund their highly anticipated webinar on “Office Peels and Home Peels” available to plastic surgeons, dermatologists, industry specialist, and aesthetic practitioners with the goal of continuing their education and improving practice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005239/en/
The webinar, which debuted worldwide to over 1,200 attendees, is just the latest event from the Academy whose mission is to provide leading education on the topic of aging science.
The webinar, moderated by IMCAS Academy Executive Editor, Dr. Dominique Du Crest, featured a renowned and diverse lineup of speakers from around the world. Mary Kay’s Dr. Michelle Hines, Director of Global Cosmetic Research & Innovation, kicked off the webinar with an overview of chemical peels and then joined experts to discuss various subjects surrounding a number of topics on the agenda. The topics covered the existential question of whether ‘to peel or not to peel’, different types of peels, peeling for darker skin types, the use of new and innovative ingredients, the dangers of peeling for patients with various skin diseases, with speakers also sharing tips on how to prolong the benefits of peeling post-procedure. The session concluded with a robust Q&A panel chaired by Dr. Uliana Gout, M.D. Alongside Dr. Hines, the featured speakers included Dr. Foteini Bageorgou, Dermatologist; Dr. Marina Landau, Dermatologist; and Dr. Mukta Sachdev, Dermatologist.
“Women of any age, anywhere in the world, want flawless skin,” said Dr. Hines. “Currently, chemical peels are a popular skin rejuvenation and skin resurfacing procedure. Professional and at-home peels offer different experiences and benefits. As there are many options available, education and awareness are important to make the best choice. Mary Kay was thrilled to provide a grant to further education and research on the topic.”
“I would like to underscore the dynamic and growing nature of our diverse community,” said Dr. Du Crest. “We have over 28,000 physician members, and with the outbreak of COVID-19, our community has expanded tremendously. Outside of our Congress, we offer webinars, sometimes twice a week, through which we create opportunities for doctors, physicians, dermatologists, and aestheticians all over the world to come together and share knowledge, expertise, and answer industry-related questions from their peers without having to travel or leave their home or office. Our e-Learning platform houses hundreds of clinical cases, numerous blog posts, over 40 webinars annually, and thousands of videos for industry professionals to be able to watch and enrich themselves on demand.”
The webinar was recorded and is available for viewing on the IMCAS Academy Library portal.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com
.
About International Course on Aging Science (IMCAS)
IMCAS was established in 1994 in Paris, France, as a congress dedicated to plastic surgeons and dermatologists. Since its inception, IMCAS has sought to bridge the knowledge gap between Plastic and Reconstructive Surgery and Dermatology, thereby generating synergies and helping bridge together these two fields. Its mission is to enable aesthetic practitioners to access quality scientific content on demand. IMCAS recently launched their e-learning platform, IMCAS Academy, which offers its subscribers instant access to instructional videos, scientific papers, expert interviews and more. For more information about IMCAS, click here: https://www.imcas.com/en
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005239/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom